NYSE:RCUSBiotechs
Can Arcus Biosciences Rebound in 2025 After Latest Cancer Trial Updates?
If you have Arcus Biosciences on your radar right now, you are not alone. Plenty of investors are asking themselves whether this biotech stock is about to turn a corner after a stretch of underperformance, or if there is more volatility ahead. With the share price closing at $13.35 and eking out a modest 0.2% gain over the last week, it might not look like much is happening. However, dig a little deeper and there are some interesting sparks.
Over the past month, Arcus Biosciences returned...